Intimation under Regulation 30 of SEBI LODR

Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No.290, Road No.6, Sy.No.33, 34P to 39, Guttala Begumpet, Jubilee Hills, Hyderabad, Shaikpet, Telangana, India-500033 T: +91 40 23635000 E: investorrelations@viyash.com Website: www.viyash.com CIN: L99999TS1985PLC196357 July 21, 2026 BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Fort, Bandra-Kurla Complex, Mumbai - 400 001 Bandra (East), Mumbai - 400 051 Scrip code: 512529 Symbol: VIYASH Subject: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) - Execution of the Sale and Purchase Agreement for acquisition of BioForLife Italia s.r.l. Dear Sir/ Madam, In continuation of our disclosure dated June 8, 2026, regarding the proposed acquisition of BioForLife Italia S.r.l., Milan, Italy, we wish to inform you that Alivira Animal Health Limited, Ireland, a step-down wholly owned subsidiary of Viyash Scientific Limited, has on July 21, 2026, executed a Sale and Purchase Agreement (“SPA”) with the shareholders of BioForLife Italia S.r.l. for acquisition of 100% of its issued and outstanding share capital. The base aggregate consideration under the SPA remains unchanged at approximately EUR 16.976 million, subject to adjustment for the net financial position in accordance with the SPA, comprising EUR 15.0 million payable at closing and approximately EUR 1.976 million as retained / deferred consideration. As part of the final agreed transaction terms, the mechanism governing the retained / deferred consideration has been revised and is linked to specified contractual-continuation conditions, with payment to be made in accordance with the SPA. Completion of the transaction is subject to receipt of the applicable Italian FDI / Golden Power clearance and satisfaction or valid waiver of the other conditions specified in the SPA. The material details of the acquisition, including the information required under Regulation 30 of the SEBI Listing Regulations read with the applicable SEBI Master Circular, were disclosed to the Stock Exchanges through our letter dated June 8, 2026. Except for the revised deferred-consideration mechanism described above, the other material details disclosed through the said letter remain unchanged. This disclosure is being made to inform the Stock Exchanges of the execution of the definitive transaction documentation. We request you to take the same on record. Yours faithfully, For Viyash Scientific Limited (Formerly known as Sequent Scientific Limited) Yoshita Vora Company Secretary & Compliance Officer